dr. pal on sequencing nivolumab in rcc
Published 10 years ago • 235 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
1:01
dr. pal on sequencing challenges for the treatment of patients with rcc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
0:48
dr. pal on preoperative immunotherapy in patients with rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
-
48:02
transforming care and outcomes with immunotherapy in stage i-iii resectable nsclc
-
6:45
primer to clinical ultrasound: renal and gallbladder
-
0:48
dr. pal discusses the role of pd-l1 in metastatic rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:31
dr. pal on biomarker development in renal cell carcinoma
-
0:41
dr. pal on molecular signatures in renal cell carcinoma
-
0:51
dr. pal on the safety profile of cabozantinib/atezolizumab in advanced rcc
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
1:03
dr. pal on the sequencing of immunotherapy for urothelial carcinoma